RT Journal Article
SR Electronic
T1 High vaccine effectiveness against COVID-19 infection and severe disease among residents and staff of long-term care facilities in Norway, November – June 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.08.21261357
DO 10.1101/2021.08.08.21261357
A1 Starrfelt, Jostein
A1 Danielsen, Anders S
A1 Kacelnik, Oliver
A1 Børseth, Anita Wang
A1 Seppälä, Elina
A1 Meijerink, Hinta
YR 2021
UL http://medrxiv.org/content/early/2021/08/09/2021.08.08.21261357.abstract
AB COVID-19 has caused high morbidity and mortality in long-term care facilities (LTCFs) worldwide. We estimated vaccine effectiveness (VE) among residents and health care workers (HCWs) in LTCFs using Cox regressions. The VE against SARS-CoV-2 infection was 81.5 (95%CI: 75.3 – 86.1 82.7%) and 81.4% (95%CI: 74.5-86.4%) ≥ 7 days after 2nd vaccine dose among residents and staff respectively. The VE against COVID-19 associated death was 93.1% among residents, no hospitalisations occurred among HCW ≥7 days after 2nd dose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was performed with no external funding as part of Norwegian Institute of Public Health mandate.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the Regional Committees for Medical and Health Research Ethics (REK sor-ost), Oslo, Norway (registration number: 122745).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will not be available